GPLB Reports No Revenue, Significant Post-Period Dilution

TL;DR

**GPLB is a shell with massive dilution coming; avoid this speculative play.**

AI Summary

Green Planet Bio Engineering Co. Ltd. (GPLB) reported no revenue or net income for the quarter ended June 30, 2025, continuing a trend of minimal operational activity. The company's financial position primarily reflects capital structure changes rather than operational performance. As of June 30, 2025, GPLB had 20,006,402 shares of common stock outstanding, an increase from 20,006,402 shares at December 31, 2024, indicating no change in common stock during the period. The company also reported 10,000,000 shares of Series A Preferred Stock outstanding as of June 30, 2025, consistent with the prior period. A significant subsequent event occurred on June 29, 2025, where the company issued 250,000,000 shares of common stock, which will dilute existing shareholders. The strategic outlook remains unclear given the lack of revenue-generating operations and reliance on capital raises.

Why It Matters

For investors, GPLB's continued lack of revenue and net income signals a highly speculative investment, with the subsequent issuance of 250,000,000 common shares on June 29, 2025, representing substantial dilution for existing shareholders. Employees face uncertainty given the absence of core business operations. Customers are not directly impacted as the company does not appear to have active products or services. The broader market impact is minimal due to GPLB's small scale and lack of competitive presence in the biological products sector, which is dominated by established players with significant R&D and market share.

Risk Assessment

Risk Level: high — The risk level is high due to the complete absence of revenue and net income for the quarter ended June 30, 2025, indicating no operational business. Furthermore, the subsequent event of issuing 250,000,000 shares of common stock on June 29, 2025, represents a significant dilution of over 1,200% compared to the 20,006,402 shares outstanding at June 30, 2025, posing extreme risk to shareholder value.

Analyst Insight

Investors should avoid GPLB given its lack of operational activity and the severe dilution from the 250,000,000 share issuance. This company appears to be a highly speculative venture with no clear path to profitability or value creation for current shareholders.

Financial Highlights

debt To Equity

N/A

revenue

$0.00

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$0.00

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $0.00 — Revenue (No revenue reported for the quarter ended June 30, 2025)
• $0.00 — Net Income (No net income reported for the quarter ended June 30, 2025)
• 20,006,402 — Common Shares Outstanding (As of June 30, 2025, unchanged from December 31, 2024)
• 10,000,000 — Series A Preferred Stock Shares (Outstanding as of June 30, 2025)
• 250,000,000 — Common Shares Issued (Subsequent event on June 29, 2025, indicating significant dilution)

Key Players & Entities

• Green Planet Bio Engineering Co. Ltd. (company) — filer of the 10-Q
• 03 Life Sciences (company) — organization name associated with the filer
• Mondo Acquisition II, Inc. (company) — former company name of GPLB
• SEC (regulator) — regulator of 10-Q filings
• $0.00 (dollar_amount) — revenue and net income for Q2 2025

FAQ

Risk Factors

• Lack of Revenue Generation [high — operational]: Green Planet Bio Engineering Co. Ltd. reported $0.00 in revenue for the quarter ended June 30, 2025. This lack of operational activity and revenue generation is a significant concern, indicating the company is not currently producing or selling any products or services.
• Reliance on Capital Raises [high — financial]: The company's financial strategy appears to be heavily reliant on capital raises, as evidenced by the significant subsequent event of issuing 250,000,000 shares of common stock on June 29, 2025. This indicates a need for external funding rather than sustainable revenue generation.
• Share Dilution [high — financial]: The issuance of 250,000,000 common shares on June 29, 2025, will substantially dilute existing shareholders. With 20,006,402 shares outstanding prior to this event, the new issuance represents a massive increase in the total share count.

Industry Context

The biological products industry, particularly for companies not focused on diagnostics, is highly research-intensive and often requires substantial capital investment for development and commercialization. Companies in this sector face intense competition, long product development cycles, and stringent regulatory hurdles. Success typically hinges on innovation, intellectual property protection, and securing ongoing funding.

Regulatory Implications

As a bio-engineering company, GPLB is subject to regulations from bodies like the FDA if its products fall under their purview. Compliance with manufacturing standards, safety protocols, and efficacy testing is critical. Failure to comply can lead to significant penalties, product recalls, and reputational damage.

What Investors Should Do

1. Monitor future capital raises and their terms.
2. Seek clarity on the company's business strategy and path to revenue generation.
3. Evaluate the impact of share dilution on existing holdings.

Key Dates

• 2025-06-30: Quarter End — Reporting period for the 10-Q, showing $0 revenue and $0 net income.
• 2025-06-29: Subsequent Event - Common Stock Issuance — 250,000,000 shares of common stock were issued, leading to significant shareholder dilution.
• 2025-08-08: Filing Date — The date the 10-Q report was filed with the SEC.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information and disclosures for Green Planet Bio Engineering Co. Ltd. for the specified quarter.)

Subsequent Event

A significant event that occurs after the balance sheet date but before the financial statements are issued or made available to shareholders. (The issuance of 250,000,000 common shares on June 29, 2025, is a critical subsequent event that will impact the company's capital structure and shareholder equity.)

Dilution

The reduction in the ownership percentage of a shareholder resulting from the issuance of new shares. (The large issuance of new shares by GPLB will significantly dilute the ownership stake of existing shareholders.)

Series A Preferred Stock

A class of preferred stock that has certain rights and privileges over common stock, often including dividend preferences or conversion rights. (GPLB has 10,000,000 shares of Series A Preferred Stock outstanding, which represents a component of its capital structure.)

Year-Over-Year Comparison

The current 10-Q for the quarter ended June 30, 2025, shows no revenue and no net income, consistent with the company's historical operational inactivity. Key metrics such as revenue growth and margins remain N/A due to the lack of operational performance. The most significant change is the subsequent event of issuing 250,000,000 common shares, which will drastically alter the company's capital structure and dilute existing shareholders, a factor not present in prior filings.

Filing Documents

• gplb_10q.htm (10-Q) — 321KB
• gplb_ex31.htm (EX-31) — 10KB
• gplb_ex32.htm (EX-32) — 4KB
• 0001654954-25-009248.txt ( ) — 1308KB
• gplb-20250630.xsd (EX-101.SCH) — 14KB
• gplb-20250630_lab.xml (EX-101.LAB) — 89KB
• gplb-20250630_cal.xml (EX-101.CAL) — 18KB
• gplb-20250630_pre.xml (EX-101.PRE) — 67KB
• gplb-20250630_def.xml (EX-101.DEF) — 20KB
• gplb_10q_htm.xml (XML) — 84KB

Financial Statements

Financial Statements 4 Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 (Unaudited) 4 5 6 7 Condensed Notes to the Financial Statements (Unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 10 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 11 Item 4.

Controls and Procedures

Controls and Procedures 11 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 12 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 12 Item 3. Defaults upon Senior Securities 12 Item 4. Reserved 12 Item 5. Other Information 12 Item 6. Exhibits 12

SIGNATURES

SIGNATURES 13 2 Table of Contents INTERIM FINANCIAL STATEMENTS The unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions under Regulation S-X of the Securities and Exchange Commission ("SEC") Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2024. The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company's financial position as of the period reporting date, and the results of its operations and cash flows for the fiscal period end. The results of operations for the fiscal period end are not necessarily indicative of the results to be expected for future quarters or the full fiscal year.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties, including, among other things, statements regarding our business strategy, future revenues and anticipated costs and expenses. Such forward-looking statements include, among others, those statements including the words "expects," "anticipates," "intends," "believes," "may," "will," "should," "could," "plans," "estimates," and similar language or negative of such terms. Our actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Item 2 "Management's Discussion and Analysis of Financial Condition and Results of Operations." You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we do not know whether we can achieve positive future results, levels of activity, performance, or goals. Actual events or results may differ materially. We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances taking place after the date of this document. 3 Table of Contents

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Green Planet Bioengineering Co., Ltd. Balance Sheets June 30, December 31, 2025 2024 (Unaudited) (Unaudited) ASSETS Current assets Cash $ - $ - TOTAL CURRENT ASSETS $ - $ - LIABILITIES AND STOCKHOLDERS' DEFICIT LIABILITIES Current liabilities Accounts payable and accrued liabilities $ 3,500 $ 5,500 Amount due to a related party 472,579 459,634 TOTAL CURRENT LIABILITIES 476,079 465,134 Commitments and Contingencies (note 6) STOCKHOLDERS' DEFICIT Preferred stock : par value of $ 0.001 per share, Authorized: 10,000,000 shares at June 30, 2025 and December 31, 2024 Issued and outstanding : 0 shares at June 30, 2025 and December 31, 2024 - - Common stock : par value $ 0.001 per share Authorized : 250,000,000 shares at June 30, 2025 and December 31, 2024 Issued and outstanding : 20,006,402 shares at June 30, 2025 and December 31, 2024 20,006 20,006 Additional paid-in capital 609,614 609,614 Retained earnings (deficit) ( 1,105,699 ) ( 1,094,754 ) TOTAL STOCKHOLDERS' DEFICIT ( 476,079 ) ( 465,134 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ - $ - See Condensed Notes to the Unaudited Financial Statements 4 Table of Contents Green Planet Bioengineering Co., Ltd. (Unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Administrative expenses $ ( 4,105 ) $ ( 10,863 ) $ ( 10,945 ) $ ( 17,328 ) Loss before income taxes ( 4,105 ) ( 10,863 ) ( 10,945 ) ( 17,328 ) Provision for income taxes - - - - $ ( 4,105 ) $ ( 10,863 ) $ ( 10,945 ) $ ( 17,328 ) Loss per share -Basic and diluted $ (*) $ (*) $ (*) $ (*) Weighted average number of shares outstanding -Basic and diluted 20,006,402 20,006,402 20,006,402 20,006,402 * Less than $.01, per share See Condensed Notes to the Unaudited Financial Statements 5 Table of Contents Green Pla

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS General Overview The Company operates as a public reorganized corporation with the business purpose to acquire or merge with an existing business operation. Results of Operations and Financial Condition for the six months ended June 30, 2025, as compared to the six months ended June 30, 2024. The Company had no active business operations for the periods ended June 30, 2025 and June 30, 2024. Expenses consist of accounting and filing fees. Liquidity and capital resources The Company had no active business operations for the six months ended June 30, 2025. Accordingly, all of the Company's cash flow needs were provided by a related party of Global Funds, the majority stockholder to pay expenses necessary as a public company. Going forward, the Company will continue to source adequate funding from future investors to execute business opportunities when they arise in the future. However, such funding and business opportunities will rely entirely on the prevailing circumstances when the funding or profitable business opportunities are identified. If such opportunities are not identified in the near term, the Company will experience delay in effecting its business plans. The financial statements have been prepared assuming that the Company will continue as going concern. The Company is currently a public reorganized shell corporation and has no current business activity. The Company's ability to continue as a going concern is dependent on continued support from a related party of Global Funds, a majority stockholder. This gives rise to substantial doubt about the Company's ability to continue as a going concern.

Risk factors

Risk factors The Company's critical accounting policies are still being applied despite the fact that Company has no ongoing business operations. Significant Estimates We prepare our financial statements in conformity with generally accepted accounting principles in the United States of America. As such, we are required to make estimates, judgments and assumptions that we believe are reasonable based upon historical experience, current trends and other factors. These estimates, judgments and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the periods presented. Actual results could be different than those estimates. Off-Balance Sheet Arrangements We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. Market Risks There has been no material change in market risks since our last Annual Report on Form 10-K for the year ended December 31, 2024. 10 Table of Contents

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK As a smaller company, we are not required to provide the information required by this Item.

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of the fiscal period end, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Limitations on Effectiveness of Controls and Procedures In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. 11

OTHER INFORMATION

PART II OTHER INFORMATION

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS None

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS None

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES None

OTHER INFORMATION

ITEM 5. OTHER INFORMATION None

E XHIBITS

ITEM 6. E XHIBITS 31 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 12 Table of Contents

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned; thereunto duly authorized this 8 th day of August, 2025. GREEN PLANET BIOENGINEERING CO., LTD. Date: August 8, 2025 By: /s/ Jordan Weingarten Jordan Weingarten President (Principal Executive Officer and Principal Financial and Accounting Officer) and Director 13

View Full Filing

View this 10-Q filing on SEC EDGAR